G3BP2-KIT drives leukemia amenable to kinase inhibition in Ph-like ALL
Ilaria Iacobucci(St. Jude Children's Research Hospital), Charles G. Mullighan(St. Jude Children's Research Hospital), Jake D. Friske(St. Jude Children's Research Hospital), Pradyuamna Baviskar(St. Jude Children's Research Hospital), Chunxu Qu(St. Jude Children's Research Hospital), Yaqi Zhao(St. Jude Children's Research Hospital), Aman Seth, Emily A. Backhaus(St. Jude Children's Research Hospital), Laura J. Janke(St. Jude Children's Research Hospital), Anjali S. Advani(Cleveland Clinic), Peter Chockley(St. Jude Children's Research Hospital), Alexander Laird(Pfizer (United States)), Reiji Fukano(St. Jude Children's Research Hospital)
Cited by 3
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Deletion of <i>IKZF1</i> and Prognosis in Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2009|1.4k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k